



## Ladislav Prikler

### Kontakt

Ladislav Prikler

## Publikationen (6)

Viktorin-Baier P, Zürn K, Güsewell S, Schiefer J, Blick N, Müntener M, Stucki P, Suter S, Prikler L, Hochreiter W, Thoeni A, Schwab C, Plasswilm L, Schmid H, Putora P, Engeler D. Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry. *BJU Int* 2020; 125:827-835.

Engeler D, Schmid H, Plasswilm L, Schiefer J, Stucki P, Suter S, Prikler L, Hochreiter W, Thöni A, Schwab C, Putora P. PSA bounce after (125)I-brachytherapy for prostate cancer as a favorable prognosticator. *Strahlenther Onkol* 2015; 191:787-791.

Schiefer J, Roth J, Krusche B, Prikler L, Leippold T, Schmid H, Lenggenhager C, Ries G, Plasswilm L, Seelentag W, Vontoggenburg F, Engeler D. Exposure of treating physician to radiation during prostate brachytherapy using iodine-125 seeds: dose measurements on both hands with thermoluminescence dosimeters. *Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]* 2009; 185:689-95.

Remmele W, Prikler L, Schmid H, Engeler D. Intermittent ureteral herniation--rare cause of flank pain. *Urologia internationalis* 2006; 77:286-8.

Scandella E, Men Y, Legler D, Gillessen Sommer S, Prikler L, Ludwig B, Groettrup M. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. *Blood* 2004; 103:1595-601.

Prikler L, Scandella E, Men Y, Engeler D, Diener P, Gillessen Sommer S, Ludwig B, Schmid H. Adaptive Immuntherapie des fortgeschrittenen Prostatakarzinoms - Cancer Testis Antigene (CTA) als mögliche Zielantigene. *Aktuel Urol* 2004; 35:326-330.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)